Myocardial failure and other severe complications can escape detection using current monitoring technologies, given the trade-offs between invasiveness, real time measurements, accessibility and accuracy of data. Due the high-risk profile of open-heart surgeries, failure to timely detect complications leads to increased mortality and morbidity, which in turn results in lower quality of life for the affected patients and increased hospitalization costs. For effective cardiac monitoring, surgeons need real time data, 24h continuous monitoring during and post-surgery (up to 7 days), and an accurate biosignal that can be trusted for immediate detection and assessment of cardiac events. No current technology enables this with low invasiveness and risk.
Cardiaccs will lead the CardiSense 2.0 project aiming to develop the next generation of cardiac sensors, in which a 3-axis accelerometer is coupled with pace leads anchoring to the pericardium. Software-assisted examination of the cardiac muscle contraction will appear on a monitor and the alert function will allow surgeons and nurses to know as soon as a complication is picked-up. This project will specifically enable: 1) the optimization and integration of novel sensor characteristics, in a pilot and independent industrial set-up; 2) gather data through pre-clinical studies to support the necessary certifications and approvals for subsequent clinical trials; 3) showcasing to clinical end-users while developing market maturation steps; and 4) promote Cardiaccs growth strategy.
The EIC Accelerator thus provides a unique opportunity for Cardiaccs to mature and showcase the potential of its technology, to raise customer awareness and overcome the remaining challenges associated with the market adoption of our product. The project is therefore key to accelerate the monetization and know-how available in-house.